{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:14:56Z","timestamp":1771013696365,"version":"3.50.1"},"reference-count":27,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.3892\/or.2013.2387","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T06:28:46Z","timestamp":1365056926000},"page":"2147-2153","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin-4 receptor \u03b1-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma"],"prefix":"10.3892","volume":"29","author":[{"given":"KAHORI","family":"SETO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUNICHI","family":"SHODA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOHISA","family":"HORIBE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EIJI","family":"WARABI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAZUNORI","family":"ISHIGE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENJI","family":"YAMAGATA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAYUKI","family":"KOHNO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TORU","family":"YANAGAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIROKI","family":"BUKAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOJI","family":"KAWAKAMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"key20180107215036_b1-or-29-06-2147","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107215036_b2-or-29-06-2147","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6602510","article-title":"State-of-the-art management of locally advanced head and neck cancer","volume":"92","author":"Seiwert","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180107215036_b3-or-29-06-2147","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"key20180107215036_b4-or-29-06-2147","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00405-008-0697-6","article-title":"Current aspects of targeted therapy in head and neck tumors","volume":"265","author":"Dietz","year":"2008","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"key20180107215036_b5-or-29-06-2147","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11864-011-0176-y","article-title":"Current treatment options for metastatic head and neck cancer","volume":"13","author":"Price","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"key20180107215036_b6-or-29-06-2147","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bjc.6602999","article-title":"Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer","volume":"94","author":"Kirby","year":"2006","journal-title":"Br J Cancer"},{"key":"key20180107215036_b7-or-29-06-2147","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","article-title":"Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107215036_b8-or-29-06-2147","doi-asserted-by":"crossref","first-page":"9903","DOI":"10.1158\/0008-5472.CAN-06-4558","article-title":"Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma","volume":"67","author":"Shimamura","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107215036_b9-or-29-06-2147","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1002\/ijc.23865","article-title":"Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma","volume":"123","author":"Ishige","year":"2008","journal-title":"Int J Cancer"},{"key":"key20180107215036_b10-or-29-06-2147","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20180107215036_b11-or-29-06-2147","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02700027","article-title":"Safty, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma","volume":"64","author":"Weber","year":"2003","journal-title":"J Neurooncol"},{"key":"key20180107215036_b12-or-29-06-2147","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.cji.0000187959.45803.0c","article-title":"Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2","volume":"29","author":"Attia","year":"2006","journal-title":"J Immunother"},{"key":"key20180107215036_b13-or-29-06-2147","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2011.04.003","article-title":"Therapeutic potential of anticancer immunotoxins","volume":"16","author":"Choudhary","year":"2011","journal-title":"Drug Discov Today"},{"key":"key20180107215036_b14-or-29-06-2147","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ejca.2010.10.021","article-title":"A novel hybrid peptide targeting EGFR-expressing cancers","volume":"47","author":"Kohno","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20180107215036_b15-or-29-06-2147","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.cji.0000162782.86008.mL","article-title":"Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor","volume":"28","author":"Garland","year":"2005","journal-title":"J Immunother"},{"key":"key20180107215036_b16-or-29-06-2147","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1056\/NEJMra001375","article-title":"Head and neck cancer","volume":"345","author":"Forastiere","year":"2001","journal-title":"N Engl J Med"},{"key":"key20180107215036_b17-or-29-06-2147","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1758-3284-1-36","article-title":"HPV & head and neck cancer: a descriptive update","volume":"1","author":"Goon","year":"2009","journal-title":"Head Neck Oncol"},{"key":"key20180107215036_b18-or-29-06-2147","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000149583","article-title":"The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize","volume":"82","author":"Bosch","year":"2008","journal-title":"Pharmacology"},{"key":"key20180107215036_b19-or-29-06-2147","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.med.58.070605.115320","article-title":"Immunotoxin treatment of cancer","author":"Pastan","year":"2007","journal-title":"Annu Rev Med"},{"key":"key20180107215036_b20-or-29-06-2147","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1208\/aapsj080363","article-title":"Immunotoxins for targeted cancer therapy (review)","volume":"8","author":"Kreitman","year":"2006","journal-title":"AAPS J"},{"key":"key20180107215036_b21-or-29-06-2147","first-page":"106","article-title":"Immunotoxins and cancer therapy","volume":"2","author":"Li","year":"2005","journal-title":"Cell Mol Immunol"},{"key":"key20180107215036_b22-or-29-06-2147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1479-5876-9-8","article-title":"Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent","volume":"9","author":"Horibe","year":"2011","journal-title":"J Transl Med"},{"key":"key20180107215036_b23-or-29-06-2147","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbrc.2011.03.030","article-title":"A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity","volume":"407","author":"Tada","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107215036_b24-or-29-06-2147","first-page":"281","article-title":"Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models","volume":"8","author":"Strome","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20180107215036_b25-or-29-06-2147","first-page":"45","article-title":"Head and neck cancers, but not benign lesions, express interleukin-4 receptors in situ","volume":"5","author":"Mehrotra","year":"1998","journal-title":"Oncol Rep"},{"key":"key20180107215036_b26-or-29-06-2147","first-page":"2981","article-title":"Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells","volume":"60","author":"Kawakami","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107215036_b27-or-29-06-2147","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1582-4934.2007.00088.x","article-title":"Recent advances in cancer stem\/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers","volume":"11","author":"Mimeault","year":"2007","journal-title":"J Cell Mol Med"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2387\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T16:50:51Z","timestamp":1515343851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,4,4]]},"published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.3892\/or.2013.2387"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2387","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]}}}